pharma-istock-598676126-kadmy-
kadmy / iStockphoto.com
22 March 2018Americas

Novartis sues Regeneron over eye treatment

Novartis has accused competitor Regeneron of patent infringement through the latter’s sale of Eylea (aflibercept) and Zaltrap (ziv-aflibercept).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
27 March 2018   GSK has revealed that it will buy Novartis out of their joint consumer healthcare business.
Americas
4 May 2021   Pharmaceutical company Novartis has abandoned its attempt to halt US imports of Regeneron’s Eylea pre-filled syringes amid concerns that such a ban could hinder public access to essential treatments.

More on this story

Big Pharma
27 March 2018   GSK has revealed that it will buy Novartis out of their joint consumer healthcare business.
Americas
4 May 2021   Pharmaceutical company Novartis has abandoned its attempt to halt US imports of Regeneron’s Eylea pre-filled syringes amid concerns that such a ban could hinder public access to essential treatments.

More on this story

Big Pharma
27 March 2018   GSK has revealed that it will buy Novartis out of their joint consumer healthcare business.
Americas
4 May 2021   Pharmaceutical company Novartis has abandoned its attempt to halt US imports of Regeneron’s Eylea pre-filled syringes amid concerns that such a ban could hinder public access to essential treatments.